BSXNEUTRAL

Revenue Growth (YoY)

11.6%

Higher than 72% of Healthcare sector peers

Updated 416h ago

Sector Performance

72th percentile

BSX

11.6%

Sector Median

6.2%

Sector Avg

4.2%

📊

Deep Analysis

Revenue growth (year-over-year, or YoY) measures the percentage increase in a company's sales compared to the same quarter one year ago.

BSX's current revenue growth of 11.6% is nearly double the healthcare sector median of 6.2%, placing the company in the 72nd percentile among its peers. No trend data is available: the year-over-year change, quarter-over-quarter change, and the direction over the last eight quarters are all listed as N/A, so there is no basis to assess momentum. The combination of a strong current growth level (well above the sector median) with no trend information suggests a solid current performance but introduces uncertainty about whether that pace is accelerating or decelerating. This metric supports the overall NEUTRAL verdict: the above-average growth rate is favorable, but the absence of trend data prevents a bullish or bearish tilt, consistent with a neutral stance.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about BSX?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does BSX's Revenue Growth (YoY) compare to its sector?

BSX's Revenue Growth (YoY) of 11.6% compares to a Healthcare sector median of 6.2%, placing it in the 72th percentile.

Who are BSX's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: ALGN (6.2%), AMGN (5.8%), CPRX (5.6%), ABT (7.8%), ZBH (9.3%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.